Table 3.
Univariate and multivariate survival analysis results
| Clinicopathological feature | Univariate-analyzed P value |
Multivariate analysis |
|
| P value | HR (95%CI) | ||
| Gender | 0.611 | ||
| Male | |||
| Female | |||
| Age | 0.000 | 0.096 | |
| < 65 yr | 0.774 (0.573-1.046) | ||
| ≥ 65 yr | 1.000 | ||
| Tumor size | 0.000 | 0.122 | |
| < 5 cm | 0.784 (0.576-1.067) | ||
| ≥ 5 cm | 1.000 | ||
| Differentiation degree | 0.108 | ||
| Middle and high differentiation | |||
| Low differentiation | |||
| T staging | 0.000 | 0.583 | |
| T1 | 0.898 | 0.879 (0.122-6.338) | |
| T2 | 0.579 | 0.797 (0.358-1.776) | |
| T3 | 0.170 | 0.739 (0.480-1.138) | |
| T4 | 1.000 | ||
| N staging | 0.000 | 0.080 | |
| N0 | 0.303 | 0.622 (0.252-1.535) | |
| N1 | 0.910 | 1.037 (0.556-1.934) | |
| N2 | 0.091 | 0.678 (0.433-1.063) | |
| N3 | 1.000 | ||
| TNM staging | 0.000 | 0.008 | |
| Stage I | 0.030 | 0.134 (0.022-0.822) | |
| Stage II | 0.004 | 0.387 (0.204-0.735) | |
| Stage III | 1.000 | ||
| Platelet counting | 0.382 | ||
| < 300 × 109/L | |||
| ≥ 300 × 109/L | |||
| CEA | 0.000 | 0.547 | |
| < 5 ng/mL | 0.912 (0.675-1.231) | ||
| ≥ 5 ng/mL | 1.000 | ||
| NLR | 0.000 | 0.003 | |
| < 3.5 | 0.626 (0.460-0.852) | ||
| ≥ 3.5 | 1.000 | ||
NLR: Neutrophil-to-lymphocyte ratio; CEA: Carcinoembryonic antigen; HR: Hazard ratio.